Search

Your search keyword '"Xia WB"' showing total 3 results
Start Over Author "Xia WB" Publisher future medicine ltd
3 results on '"Xia WB"'

1. The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women.

Author

Wang JY, Zhou PR, Liu Y, Xu XJ, Ma DD, Xia WB, Jiang Y, Wang O, Xing XP, and Li M

Subjects
Alanine Transaminase blood, Alkaline Phosphatase blood, Asian People, Biomarkers blood, Bone Diseases, Metabolic drug therapy, Bone Diseases, Metabolic genetics, Bone Diseases, Metabolic physiopathology, Collagen Type I blood, Creatinine blood, Genetic Association Studies, Humans, Osteoporosis, Postmenopausal drug therapy, Osteoporosis, Postmenopausal genetics, Osteoporosis, Postmenopausal physiopathology, Peptides blood, Polymorphism, Single Nucleotide, Prospective Studies, Alendronate therapeutic use, Bone Density drug effects, Bone Density Conservation Agents therapeutic use, Bone Remodeling drug effects, Intercellular Signaling Peptides and Proteins genetics
Abstract

Aim: To investigate the correlation between DKK1 polymorphisms with bone phenotypes and response to alendronate treatment., Materials & Methods: Five tag single nucleotide polymorphisms of DKK1 were analyzed in 639 Chinese postmenopausal women with osteoporosis or osteopenia. Bone mineral density (BMD), β-CTX and ALP were measured before and after alendronate treatment., Results: Genotypes at rs1896367, rs1528877 and rs2241529 correlated to baseline BMD (p < 0.05). rs1528877 and rs2241529 polymorphisms correlated to baseline β-CTX levels (p < 0.05). rs2241529 polymorphisms of DKK1 had a small influence on the skeletal response to alendronate treatment (p < 0.05)., Conclusion: DKK1 polymorphisms may correlate to baseline BMD and serum β-CTX levels, but present a weak effect on the response to alendronate.

Published
2016
Full Text
View/download PDF

2. SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.

Author

Zhou PR, Xu XJ, Zhang ZL, Liao EY, Chen DC, Liu J, Wu W, Jiang Y, Wang O, Xia WB, Xing XP, Xu L, and Li M

Subjects
Adaptor Proteins, Signal Transducing, Adult, Aged, Asian People genetics, Biomarkers metabolism, Bone Density drug effects, Bone Density genetics, Bone Density Conservation Agents therapeutic use, Female, Humans, Lumbar Vertebrae drug effects, Middle Aged, Prospective Studies, Alendronate therapeutic use, Bone Morphogenetic Proteins genetics, Genetic Markers genetics, Osteoporosis drug therapy, Osteoporosis genetics, Polymorphism, Genetic genetics, Postmenopause drug effects, Postmenopause genetics
Abstract

Aim: To investigate the association between SOST gene polymorphisms and response to alendronate treatment., Materials & Methods: 639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment. Polymorphisms of SOST were analyzed. Bone mineral density (BMD), serum ALP and β-CTX levels were measured. The correlation of SOST polymorphisms with changes of BMD and bone biomarkers after treatment was analyzed., Results: rs1234612 and rs851054 polymorphisms were correlated to baseline lumbar spine BMD (p < 0.05). After 12 months of treatment rs1234612 and rs865429 polymorphisms were correlated to BMD changes at the lumbar spine (p < 0.05) or femoral neck (p < 0.05), respectively., Conclusion: The polymorphisms of SOST are genetic factors affecting bone health and response to alendronate in Chinese postmenopausal women.

Published
2015
Full Text
View/download PDF

3. LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.

Author

Zhou PR, Liu HJ, Liao EY, Zhang ZL, Chen DC, Liu J, Wu W, Xing XP, Xia WB, Xu L, and Li M

Subjects
Adult, Aged, Biomarkers metabolism, Bone Density drug effects, Bone Density genetics, Collagen Type I genetics, Collagen Type I metabolism, Female, Genotype, Humans, Low Density Lipoprotein Receptor-Related Protein-5 metabolism, Lumbar Vertebrae drug effects, Middle Aged, Osteogenesis drug effects, Osteogenesis genetics, Osteoporosis metabolism, Postmenopause metabolism, Alendronate therapeutic use, Low Density Lipoprotein Receptor-Related Protein-5 genetics, Osteoporosis drug therapy, Osteoporosis genetics, Polymorphism, Genetic genetics, Postmenopause drug effects, Postmenopause genetics
Abstract

Aim: To investigate the association between LRP5 gene polymorphisms and response to alendronate in Chinese osteoporotic women., Materials & Methods: Six hundred and thirty nine Chinese postmenopausal women with osteopenia or osteoporosis were included and received alendronate treatment. The A1330V polymorphism of LRP5 was investigated. Bone mineral density (BMD) and bone turnover markers (ALP and β-isomerized carboxy-telopeptide of type I collagen [β-CTX]) were measured before and after treatment. The correlation of LRP5 polymorphisms with changes in BMD and bone turnover biomarkers were analyzed after treatment., Results: After 12 months of treatment, participants with CC and CT genotypes had a larger increase in lumbar spine BMD and a larger decrease in serum β-CTX and ALP levels than those with TT genotype (all p < 0.001). No significant genotype-treatment interaction was found in hip BMD., Conclusion: The A1330V polymorphism of LRP5 is possibly correlated with response to alendronate treatment in Chinese women with osteoporosis, and the TT genotype could possibly predict a weak response to alendronate.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results